Area of research
Immunology · Dermatology
Research interest
Research interests include Medicine, Psoriasis, Generalized pustular psoriasis, Dermatology, Ustekinumab, and Pustular psoriasis.
A genome-wide meta-analysis of palmoplantar pustulosis implicates TH2 responses and cigarette smoking in disease pathogenesis
The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis
Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis
Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion
Trial of Spesolimab for Generalized Pustular Psoriasis
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare
Anakinra for palmoplantar pustulosis: results from a randomized, double‐blind, multicentre, two‐staged, adaptive placebo‐controlled trial (APRICOT)*
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update
Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, <scp>BADBIR</scp> )
IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis
Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis
Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study
Genome-wide meta-analysis implicates mediators of hair follicle development and morphogenesis in risk for severe acne
European consensus statement on phenotypes of pustular psoriasis
Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis
Exposure to biological therapies during conception and pregnancy: a systematic review
AP1S3 Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 Production
Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris
Establishing an Academic–Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy
Effectiveness Of Spacers For The Delivery Of Small Particle (qvar (R)) And Standard Sized Particle (fluticasone Propionate) Inhaled Corticosteroid In Patients With Asthma
2015cited by 0position: middle
AP1S3 Mutations Are Associated with Pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking
IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis
Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools
Rare Pathogenic Variants in IL36RN Underlie a Spectrum of Psoriasis-Associated Pustular Phenotypes